R&D channel feed – Endpoints News

R&D channel feed

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

9 years ago

Pfizer launching first US mAb biosimilar with Remicade knockoff, but you can forget about any fire sale

9 years ago

PTC shares plunge anew after FDA slaps down Duchenne drug for a second time

9 years ago

Safety threat forces FDA to put a hold on Regeneron, Teva’s big NGF pain drug fasinumab

9 years ago

Now with actual data in hand, Celgene touts an early response for Crohn’s drug mongersen

9 years ago

Sarepta lands a valuable priority review voucher on Exondys 51 OK

9 years ago

Post-merger, gene therapy player Adverum makes Amber Salzman CEO, delays a clinical trial start

9 years ago

FDA's controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin

9 years ago

Tesaro v Myriad: Niraparib partners squared off in court as Tesaro tried to quash a contrary press release

9 years ago

Merck KGaA: This time we’ve got our R&D act together (seriously)

9 years ago

TG Therapeutics maps a shortcut to the FDA with lead drug for CLL

9 years ago

Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea

9 years ago

Adaptimmune looks to salvage ovarian cancer study by adding fludarabine to prep patients

9 years ago

Tiny RXi bags an option to buy CAR-T fledgling MirImmune

9 years ago

AstraZeneca records another R&D setback, triggering a meltdown at Synairgen

9 years ago

The promise of designer microbes inspires a $130M mega-round for Zymergen

9 years ago

Illumina shares tank after sequencing giant falls short on revenue

9 years ago

Novartis-backed Gamida Cell grabs a breakthrough trophy for experimental cell treatment

9 years ago

Supernus gets a (temporary) boost as ADHD drug clears PhIIb hurdle

9 years ago

Deaths, accusations of insider trading and an early warning from Boehringer stir Hanmi controversy

9 years ago

GSK attempts to remake itself in China with local ties

9 years ago

Takeda adds a $790M discovery deal to an ongoing R&D overhaul

9 years ago

Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers

9 years ago

Novartis heads to the finish line with CDK 4/6 blockbuster contender ribociclib

9 years ago

First page Previous page 315 316 317318319 320 321 Next page Last page